RU96107419A - BENZOFURANI, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS PRODUCTION - Google Patents

BENZOFURANI, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS PRODUCTION

Info

Publication number
RU96107419A
RU96107419A RU96107419/04A RU96107419A RU96107419A RU 96107419 A RU96107419 A RU 96107419A RU 96107419/04 A RU96107419/04 A RU 96107419/04A RU 96107419 A RU96107419 A RU 96107419A RU 96107419 A RU96107419 A RU 96107419A
Authority
RU
Russia
Prior art keywords
formula
compound
piperazinyl
group
denotes
Prior art date
Application number
RU96107419/04A
Other languages
Russian (ru)
Other versions
RU2159238C2 (en
Inventor
Бате Андреас
Хелферт Бернд
Беттхер Хеннинг
Шустер Курт
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19514567A external-priority patent/DE19514567A1/en
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of RU96107419A publication Critical patent/RU96107419A/en
Application granted granted Critical
Publication of RU2159238C2 publication Critical patent/RU2159238C2/en

Links

Claims (7)

1. Бензофураны формулы I
Figure 00000001

где R1 - NH2 1-пиперазинил или 4-R3-пиперазинил;
R2 - H, Cl, Br, OH или OA;
R3 - бензил или само по себе известную, защитную для аминной функции группу;
X - CN, COOH, COOA, COOPh, COOCH2Ph, COOPy, CONR4R5 или CO-Гет;
R4 и R5 - каждый независимо друг от друга H, A или бензил;
A - алкил с 1 - 4 C-атомами;
Ph - фенил;
Гет - имидазол-1-ил, триазол-1-ил или тетразол-1-ил;
Py - пиридил,
а также их соли.
1. Benzofurans of the formula I
Figure 00000001

where R 1 is NH 2 1-piperazinyl or 4-R 3 -piperazinyl;
R 2 - H, Cl, Br, OH or OA;
R 3 is benzyl or a group that is known to be protective for the amine function;
X — CN, COOH, COOA, COOPh, COOCH 2 Ph, COOPy, CONR 4 R 5, or CO-Get;
R 4 and R 5 are each independently H, A, or benzyl;
A is alkyl with 1-4 C-atoms;
Ph is phenyl;
Get-imidazol-1-yl, triazol-1-yl or tetrazol-1-yl;
Py - pyridyl,
and their salts.
2. Бензофураны формулы I по п.1, представляющие собой:
а) этиловый эфир 5-аминобензофуран-2-карбоновой кислоты и его соли,
б) 5-(1-пиперазинил) бензофуран-2-карбоновая кислота и ее соли,
в) этиловый эфир 5-(1-пиперазинил) бензофуран-2-карбоновой кислоты и его соли,
г) этиловый эфир 5-(4-терт.-бутилоксикарбонил-1-пиперазинил)-бензофуран-2-карбоновой кислоты,
д) 5-(4-трет.-бутилоксикарбонил-1-пиперазинил) бензофуран-2-карбоксамид,
е) 5-(1-пиперазинил) бензофуран-2-карбоксамид.
2. Benzofurans of the formula I according to claim 1, which are:
a) 5-aminobenzofuran-2-carboxylic acid ethyl ester and its salt,
b) 5- (1-piperazinyl) benzofuran-2-carboxylic acid and its salts,
c) 5- (1-piperazinyl) benzofuran-2-carboxylic acid ethyl ester and its salt,
d) 5- (4-tert.-butyloxycarbonyl-1-piperazinyl) benzofuran-2-carboxylic acid ethyl ester,
d) 5- (4-tert.-butyloxycarbonyl-1-piperazinyl) benzofuran-2-carboxamide,
e) 5- (1-piperazinyl) benzofuran-2-carboxamide.
3. Способ получения бензофуранов формулы I по п.1, а также их солей, отличающийся тем, что соединение, которое соответствует формуле I, где R1 обозначает нитрогруппу, обычным образом восстанавливают, или соединение, которое соответствует формуле I, где R1 обозначает NH2-группу, вводят во взаимодействие с соединением формулы II
R6N(CH2CH2X1)2,
где R6 - H или бензил;
X1 - Cl, Br, J, OH или реакционноспособная, функционально измененная OH-группа;
или соединение, которое соответствует формуле I, где R1 обозначает 1-пиперазинильный остаток, путем введения известной защитной для аминной функции группы превращают в соединение формулы I, где R1 обозначает 4-R3-пиперазинильный остаток, где R3 имеет указанное значение или соединение, которое соответствует формуле I, где X обозначает COOA-группу, где A имеет указанное значение, превращают в другое соединение формулы (I), в которой X обозначает CONR4R5, где R4 и R5 имеют указанные значения, или соединение, которое соответствует формуле I, где X обозначает COOH-группу, превращают в другое соединение формулы I, в которой X обозначает CO-Гет, где Гет имеет указанное значение, или соединение, которое соответствует формуле I, где R1 обозначает 4-R3-пиперазинильную группу, в которой R3 имеет указанное значение, путем отщепления защитной группы превращают в соединение формулы I, в которой R1 обозначает 1-пиперазинил, и/или основание формулы I путем обработки кислотой превращают в одну из его солей.
3. The method of obtaining benzofurans of the formula I according to claim 1, as well as their salts, characterized in that the compound that corresponds to the formula I, where R 1 denotes a nitro group, is reduced in the usual way, or the compound that corresponds to formula I, where R 1 denotes NH 2 group, enter into interaction with the compound of the formula II
R 6 N (CH 2 CH 2 X 1 ) 2 ,
where R 6 is H or benzyl;
X 1 - Cl, Br, J, OH, or a reactive, functionally modified OH group;
or a compound that corresponds to formula I, where R 1 denotes a 1-piperazinyl residue, by introducing a known protective function for the amine function of the group into a compound of formula I, where R 1 denotes 4-R 3- piperazinyl residue, where R 3 has the indicated meaning or a compound that corresponds to formula I, where X denotes a COOA group, where A has the indicated meaning, is converted to another compound of formula (I), in which X represents CONR 4 R 5 , where R 4 and R 5 have the indicated meanings, or the compound which corresponds to the formula I, where X denotes t COOH group, is converted to another compound of formula I, in which X is CO-Get, where Geht has the indicated value, or a compound that corresponds to Formula I, where R 1 is 4-R 3 -piperazinyl group, in which R 3 has the indicated value, by cleaving the protective group into a compound of formula I, in which R 1 is 1-piperazinyl, and / or the base of formula I is converted into one of its salts by treatment with acid.
4. Соединения формулы I по п.1 в качестве промежуточных продуктов для синтеза лекарственных средств. 4. The compounds of formula I according to claim 1 as intermediates for the synthesis of drugs. 5. Способ получения фармацевтических композиций, отличающийся тем, что эффективное количество соединения формулы I по п.1 и/или одной из его физиологически приемлемых солей вместе по меньшей мере с одним твердым, жидким или полужидким носителем или вспомогательным веществом доводят до пригодной дозировочной формы. 5. A method of producing pharmaceutical compositions, characterized in that an effective amount of a compound of formula I according to claim 1 and / or one of its physiologically acceptable salts together with at least one solid, liquid or semi-liquid carrier or auxiliary substance is brought to a suitable dosage form. 6. Фармацевтическая композиция, отличающаяся тем, что в качестве активного вещества она содержит по меньшей мере одно соединение формулы I по п. 1 и/или одну из его физиологически приемлемых солей в эффективном количестве. 6. A pharmaceutical composition, characterized in that, as an active substance, it contains at least one compound of the formula I according to claim 1 and / or one of its physiologically acceptable salts in an effective amount. 7. Соединения формулы I по п.1 и их физиологически приемлемые соли для борьбы с заболеваниями. 7. The compounds of formula I according to claim 1 and their physiologically acceptable salts for combating diseases.
RU96107419/04A 1995-04-20 1996-04-17 Benzofurans and method of preparation thereof RU2159238C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19514567A DE19514567A1 (en) 1995-04-20 1995-04-20 Benzofurans
DE19514567.4 1995-04-20

Publications (2)

Publication Number Publication Date
RU96107419A true RU96107419A (en) 1998-07-20
RU2159238C2 RU2159238C2 (en) 2000-11-20

Family

ID=7759973

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96107419/04A RU2159238C2 (en) 1995-04-20 1996-04-17 Benzofurans and method of preparation thereof

Country Status (22)

Country Link
US (2) US5723614A (en)
EP (2) EP1215210B1 (en)
JP (2) JP3874837B2 (en)
KR (1) KR100444385B1 (en)
CN (1) CN1181067C (en)
AT (2) ATE342893T1 (en)
AU (1) AU704495B2 (en)
CA (1) CA2174494C (en)
CZ (1) CZ294697B6 (en)
DE (3) DE19514567A1 (en)
DK (2) DK0738722T3 (en)
ES (2) ES2201143T3 (en)
HU (1) HU226684B1 (en)
NO (1) NO961579L (en)
PL (1) PL189175B1 (en)
PT (2) PT738722E (en)
RU (1) RU2159238C2 (en)
SI (1) SI0738722T1 (en)
SK (2) SK284862B6 (en)
TW (1) TW335396B (en)
UA (1) UA45958C2 (en)
ZA (1) ZA963155B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942489A (en) * 1996-05-03 1999-08-24 The Administrators Of The Tulane Educational Fund HGH-RH(1-29)NH2 analogues having antagonistic activity
TW518218B (en) * 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
DE19932314A1 (en) * 1999-07-10 2001-01-11 Merck Patent Gmbh Benzofuran derivatives
DE19958496A1 (en) * 1999-12-04 2001-06-07 Merck Patent Gmbh Process for the preparation of 5- (1-piperazinyl) -benzofuran-2-carboxamide by transition metal-catalyzed amination
UA76758C2 (en) * 2001-06-19 2006-09-15 Мерк Патент Гмбх Polymorph forms of hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine
DE10305739A1 (en) * 2003-02-11 2004-08-19 Merck Patent Gmbh New indolyl-substituted benzofuran derivatives, are 5-HT(1A) agonists and 5-HT reuptake inhibitors useful e.g. as anxiolytic, antidepressant, neuroleptic and/or antihypertensive agents
DE102005019670A1 (en) * 2005-04-26 2006-11-02 Merck Patent Gmbh Preparation of 5-(4-(4-(5-cyano-3-indolyl)-butyl)-1-piperazinyl)-benzofuran-2-carboxamide, comprises reacting a heterocyclic compound with a carbonitrile compound; and/or converting the obtained benzofuran compound to its salt
EP2110374A1 (en) * 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
SG173757A1 (en) * 2009-03-10 2011-09-29 Takeda Pharmaceutical Benzofuran derivatives
CN102267985B (en) * 2011-06-15 2015-12-09 上海医药工业研究院 The preparation method of vilazodone or its hydrochloride
WO2013114338A1 (en) * 2012-02-01 2013-08-08 Ranbaxy Laboratories Limited Process for the preparation of vilazodone or its pharmaceutically acceptable salts
US9969721B2 (en) * 2012-04-12 2018-05-15 Alembic Pharmaceuticals Limited Process for the preparation of vilazodone hydrochloride and its amorphous form
WO2013175499A2 (en) * 2012-04-20 2013-11-28 Cadila Healthcare Limited Polymorphic form of 5-(4-[4-(5-cyano-1h-indol-3- yl)butyl]piperazin-1-yl) benzofuran-2-carboxamide
WO2013175361A1 (en) * 2012-05-24 2013-11-28 Ranbaxy Laboratories Limited Process for the preparation of vilazodone hydrochloride
CN102702180A (en) * 2012-05-25 2012-10-03 吉林三善恩科技开发有限公司 Vilazodone organic pharmaceutical cocrystal and preparation method thereof
WO2013182946A2 (en) * 2012-06-06 2013-12-12 Ranbaxy Laboratories Limited Process for the preparation of vilazodone hydrochloride
WO2014006637A2 (en) 2012-07-02 2014-01-09 Symed Labs Limited Improved process for preparing benzofuran-2-carboxamide derivatives
CA2884676A1 (en) 2012-09-12 2014-03-20 Apotex Pharmachem Inc. Processes for the preparation of 3-alkyl indoles
ITMI20121576A1 (en) * 2012-09-21 2014-03-22 Olon Spa PROCEDURE FOR THE PREPARATION OF VILAZODONE
WO2014049609A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Novel salts of vilazodone
WO2014061000A1 (en) 2012-10-19 2014-04-24 Ranbaxy Laboratories Limited Process for the preparation of vilazodone or pharmaceutically acceptable salt thereof
WO2014061004A2 (en) * 2012-10-19 2014-04-24 Ranbaxy Laboratories Limited Process for the preparation of vilazodone or pharmaceutically acceptable salt thereof
WO2014064715A2 (en) * 2012-10-22 2014-05-01 Cadila Healthcare Limited Amorphous form of vilazodone hydrochloride and process for preparing thereof
CN103044370A (en) * 2012-12-28 2013-04-17 山东邹平大展新材料有限公司 Preparation method of 5-(piperazinyl-1-yl) benzofuranyl-2-carboxamide
CN104045608B (en) * 2013-03-11 2016-06-01 天津药物研究院有限公司 A kind of substituted piperazine like compound and prepare the method for vilazodone intermediate
IN2013MU02001A (en) 2013-06-12 2015-05-29 Lupin Ltd
CN103360373B (en) * 2013-07-12 2016-06-15 苏州永健生物医药有限公司 The synthetic method of vilazodone intermediate and salt thereof
CN103819433A (en) * 2013-11-27 2014-05-28 上海威翼化工有限公司 Method for synthesizing piperazine-benzofuran compound
CN105801566A (en) * 2014-12-30 2016-07-27 山东方明药业集团股份有限公司 Preparation method of vilazodone hydrochloride
CN107540646B (en) * 2017-08-29 2020-12-01 连云港恒运药业有限公司 Synthesis method of vilazodone intermediate
CN109438403A (en) * 2018-12-28 2019-03-08 凯瑞斯德生化(苏州)有限公司 A kind of preparation method of 5- aminobenzofur -2- Ethyl formate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4333254A1 (en) * 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidines and piperazines
JP2990042B2 (en) * 1994-06-06 1999-12-13 吉富製薬株式会社 Novel fused ring carboxylic acid derivative or salt thereof, and pharmaceutical use thereof
CA2168858A1 (en) * 1994-06-06 1995-12-14 Shinichiro Ono Novel fused-ring carboxylic acid compound or salt thereof, and medicinal use thereof

Similar Documents

Publication Publication Date Title
RU96107419A (en) BENZOFURANI, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS PRODUCTION
RU99109576A (en) AMINES AMINOTIOPHENACARBONIC ACID AND THEIR APPLICATION
US5569674A (en) Heteroacetic acid derivatives
CA1261837A (en) 4-vinylbenzoic acid derivatives; process for preparing the same and their use as ligands and therapeutic agents
US5215738A (en) Benzamide and nicotinamide radiosensitizers
KR960037673A (en) Benzofuran
JP5935857B2 (en) Bicyclic compounds and their pharmaceutical uses
ES2540232T3 (en) TOFA analogues useful in the treatment of dermatological disorders or conditions
RU96118917A (en) ARYLALKYL-DIAZINONES, METHOD FOR THEIR PRODUCTION, CONTAINING THEIR PHARMACEUTICAL COMPOSITION, METHOD FOR ITS OBTAINING, METHOD FOR COMBATING DISEASES
RU99110944A (en) THYENOPYRIMIDINES WITH INHIBITING ACTION WITH RESPECT TO PHOSPHODYSTRASE V (PDE V)
JPH05320153A (en) Substituted 5-(2-((2-aryl-2-hydroxyethyl)- amino)-propyl)-1,3-benzodiox
SU1588740A1 (en) Hydrochlorides of diphenyl propylamine possessing antianginal activity
RU99105564A (en) METHOD OF OBTAINING COMPOUNDS OF ESTEINASCIDINE RANGE
JPH07304735A (en) ((hydroxyphenylamino)carbonyl)pyrrole
RU2000102920A (en) DERIVATIVES OF PIPERAZINE
RU99105211A (en) ARILALKANOILPYRIDAZINES
PL163045B1 (en) Method of obtaining novel derivatives of 1,3-dioxane-alkenic acid
EP1546111A2 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
RU96107677A (en) Arylalkyl-pyridazinones, METHOD FOR PRODUCING THEM, PHARMACEUTICAL COMPOSITION, METHOD FOR PRODUCING IT, MEDICINE
EA199801000A1 (en) DERIVATIVES OF ALKYLAMINOBENZOIAZOLE AND -BENZOXOL
EP0022118A1 (en) Derivatives of sulfonyl aniline, process for their preparation and their use in therapy
EP0486386A2 (en) Novel derivatives of N-benzoylproline, process for their preparation and drugs containing them
RU95113434A (en) Dimethylbenzofurans and dimethylbenzopyrans, their use as 5-ht3-antagonists, method of synthesis, pharmaceutical composition
FR2584400A1 (en) ESTERS AND AMIDES OF EICOSATRIYNOIC ACID AND THEIR APPLICATION IN PHARMACY AND COSMETICS
RU97117590A (en) Hydroxamic Acid Pyrrolidinyl Derivatives and Method for Their Production